To extend and expand these observations, we tested its efficacy in two preclinical models of AML: an aggressive and systemic model using MOLM-13 cells and a robust FLT3-ITDMUT-Luc+ PDX model. The gene discussed is FLT3; the disease is acute myeloid leukemia.